期刊
ONCOTARGETS AND THERAPY
卷 14, 期 -, 页码 2563-2573出版社
DOVE MEDICAL PRESS LTD
DOI: 10.2147/OTT.S297785
关键词
dihydroartemisinin; anti-tumor drugs; sensitizer; molecular mechanism
资金
- Applied Foundational Research Program of Sichuan Province [2021YJ0202]
- Science and Technology Support Program of Nanchong [16YFZJ0133, 18SXHZ0514, 18SXHZ0579]
DHA, a derivative of artemisinin developed in China, exhibits anticancer activities and enhances the efficacy of chemotherapy, targeted therapy, and radiotherapy. The mechanisms of DHA on different tumors vary, highlighting the potential for DHA as a sensitizer for cancer therapy.
Cancer is one of the major threats to human health. Although humans have struggled with cancer for decades, the efficacy of treatments for most tumors is still very limited. Dihydroartemisinin (DHA) is a derivative of artemisinin, a first-line antimalarial drug originally developed in China. Beyond the anti-malarial effect, DHA has also been reported to show anti-inflammatory, anti-parasitosis, and immune-modulating properties in vitro and in vivo. Furthermore, an increasing number of studies report that DHA possesses anticancer activities on a wide range of cancer types both in vitro and in vivo, as well as enhances the efficacy of chemotherapy, targeted therapy, and even radiotherapy. However, the mechanisms of DHA on different tumors differ in various ways. In this review, we intend to summarize how DHA sensitizes cancer cells to anti-cancer therapies, highlight its molecular mechanisms and pharmacological effects in vitro and in vivo as well as in current clinical trials, and discuss potential issues concerning DHA. Hopefully, more attention will be paid to DHA as a sensitizer for cancer therapy in the future.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据